Lab
Physicians Immunodiagnostic Laboratory, INC.
Physicians Immunodiagnostic Laboratory, INC. was paid $6.96M by Medicaid between Jan 2018 and Dec 2024, across 115 billing codes. Its largest line is 87491, Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe — 19% of everything it billed.
33Billing provider infoPHYSICIANS IMMUNODIAGNOSTIC LABORATORY, INC.
BURBANK, CA 91502
BURBANK, CA 91502
33aNPI1548225428assigned 04/20/2006
33bProvider typeClinical Medical Laboratory
28Total paid$6.96M
24GClaims473,524
24DCodes billed115
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in California
Rank by total paid#90 of 561
Median peer was paid$222K
This provider vs. median31×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 152,295 | $2.03M | |
| 2019 | 82,804 | $1.17M | |
| 2020 | 55,421 | $1.10M | |
| 2021 | 71,228 | $1.25M | |
| 2022 | 41,085 | $625K | |
| 2023 | 46,943 | $587K | |
| 2024incomplete | 23,748 | $200K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 19% | 44,898 | 41,104 | $1.30M |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 19% | 44,937 | 41,168 | $1.29M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 9.0% | 7,655 | 7,109 | $623K |
| 88142 | 6.7% | 26,683 | 25,211 | $464K | |
| 86703 | 5.9% | 36,813 | 34,028 | $413K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 4.1% | 9,357 | 8,383 | $288K |
| 80055 | 4.0% | 8,637 | 8,611 | $281K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 3.7% | 5,083 | 4,789 | $256K |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | 2.8% | 1,209 | 1,207 | $195K |
| 86592 | 2.2% | 42,883 | 40,274 | $153K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.1% | 31,248 | 29,475 | $144K |
| 80061 | Lipid panel | 1.7% | 16,223 | 15,691 | $121K |
103 more codes
| 84443 | Thyroid stimulating hormone (TSH) | 1.5% | 12,172 | $107K |
| 80053 | Comprehensive metabolic panel | 1.4% | 18,260 | $96K |
| 84702 | 1.2% | 7,573 | $87K | |
| 80050 | General health panel | 1.2% | 2,177 | $84K |
| 83036 | Hemoglobin; glycosylated (A1C) | 1.1% | 13,549 | $76K |
| 87481 | 1.0% | 2,267 | $71K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 712 | $64K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 2,159 | $63K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 10,147 | $61K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 5,460 | $59K |
| 87077 | <1% | 7,378 | $51K | |
| 87511 | <1% | 1,481 | $50K | |
| 88141 | <1% | 3,951 | $38K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 1,083 | $33K |
| 82950 | <1% | 8,463 | $32K | |
| 86803 | <1% | 3,192 | $30K | |
| 87070 | <1% | 4,541 | $30K | |
| 84436 | <1% | 6,014 | $29K | |
| 84479 | <1% | 5,337 | $27K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,763 | $25K |
| 87184 | <1% | 5,882 | $23K | |
| 87081 | <1% | 3,808 | $19K | |
| 81003 | <1% | 11,443 | $18K | |
| 84439 | <1% | 4,135 | $17K | |
| 84153 | <1% | 1,586 | $16K | |
| 84481 | <1% | 1,291 | $15K | |
| 83090 | <1% | 952 | $14K | |
| 80306 | <1% | 995 | $13K | |
| 83655 | <1% | 2,164 | $12K | |
| 84144 | <1% | 610 | $10K | |
| 82570 | <1% | 2,972 | $10K | |
| 80305 | <1% | 892 | $9K | |
| 82043 | <1% | 2,704 | $9K | |
| 86787 | <1% | 733 | $8K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 155 | $7K |
| 87210 | <1% | 2,089 | $7K | |
| 82951 | <1% | 708 | $7K | |
| 82728 | <1% | 1,229 | $7K | |
| 82607 | <1% | 1,668 | $6K | |
| G2024 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source | <1% | 309 | $6K |
| 87340 | <1% | 1,208 | $6K | |
| 84550 | <1% | 2,752 | $6K | |
| 82746 | <1% | 976 | $5K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 13 | $5K |
| 82952 | <1% | 1,500 | $5K | |
| 84480 | <1% | 625 | $4K | |
| 86762 | <1% | 550 | $4K | |
| 86708 | <1% | 435 | $4K | |
| 82947 | <1% | 1,409 | $4K | |
| 83540 | <1% | 1,117 | $3K | |
| 86706 | <1% | 406 | $3K | |
| 86850 | <1% | 1,177 | $3K | |
| 86901 | <1% | 733 | $2K | |
| 86038 | <1% | 699 | $2K | |
| 83550 | <1% | 823 | $2K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 34 | $2K |
| 85651 | <1% | 3,308 | $2K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 5,138 | $2K |
| 86481 | <1% | 82 | $2K | |
| 86140 | <1% | 2,595 | $2K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 95 | $1K |
| 80076 | <1% | 506 | $1K | |
| 86900 | <1% | 678 | $1K | |
| 86704 | <1% | 253 | $1K | |
| 86431 | <1% | 577 | $924.08 | |
| 81001 | <1% | 1,198 | $874.81 | |
| 86003 | <1% | 67 | $858.35 | |
| 87625 | <1% | 25 | $836.92 | |
| 84156 | <1% | 368 | $815.52 | |
| 83970 | <1% | 85 | $776.16 | |
| 83735 | <1% | 882 | $736.43 | |
| 82670 | <1% | 30 | $716.59 | |
| 86780 | <1% | 66 | $678.52 | |
| 80074 | <1% | 50 | $664.51 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 295 | $446.97 |
| 85610 | <1% | 350 | $415.27 | |
| 82272 | <1% | 195 | $405.50 | |
| 84100 | <1% | 653 | $395.19 | |
| 82465 | <1% | 125 | $378.97 | |
| 86376 | <1% | 58 | $375.20 | |
| 82785 | <1% | 41 | $320.15 | |
| 85730 | <1% | 191 | $312.94 | |
| 86735 | <1% | 28 | $292.04 | |
| 82248 | <1% | 167 | $290.86 | |
| 86765 | <1% | 28 | $288.40 | |
| 86635 | <1% | 12 | $245.76 | |
| 86039 | <1% | 97 | $245.13 | |
| 86160 | <1% | 259 | $243.42 | |
| 86593 | <1% | 66 | $241.75 | |
| 82378 | <1% | 206 | $221.16 | |
| 85018 | <1% | 120 | $193.92 | |
| 84403 | <1% | 14 | $177.84 | |
| 85014 | <1% | 72 | $153.04 | |
| 84478 | <1% | 68 | $118.89 | |
| 86171 | <1% | 12 | $109.56 | |
| 86063 | <1% | 39 | $93.10 | |
| 86301 | <1% | 28 | $34.16 | |
| 82550 | <1% | 84 | $27.07 | |
| 85007 | <1% | 22 | $26.83 | |
| 87040 | <1% | 16 | $26.04 | |
| 82270 | <1% | 161 | $20.26 | |
| 81015 | <1% | 13 | $2.48 | |
| 87181 | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRAMZI, ALFRED (CFO)